-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 BgE2Uwdo6NtdJb98h46phQgx75NlR7BzU0C6M1KRROV6JiVaBwDqa5+ALQvMi65F
 QkD045bLHeAGCwyZhwXWQg==

<SEC-DOCUMENT>0001130319-06-000220.txt : 20060327
<SEC-HEADER>0001130319-06-000220.hdr.sgml : 20060327
<ACCEPTANCE-DATETIME>20060327105954
ACCESSION NUMBER:		0001130319-06-000220
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060327
FILED AS OF DATE:		20060327
DATE AS OF CHANGE:		20060327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		06710957

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o30790e6vk.htm
<DESCRIPTION>FORM 6-K: PRESS RELEASE DATED MARCH 27TH, 2006
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 6-K: Press Release Dated March 27th, 2006</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center"><FONT size="4"><B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
</FONT>
<FONT size="3"><B>Washington, D.C. 20549</B>
</FONT>

<P align="center"><FONT size="5"><B>Form 6-K</B>
</FONT>


<P align="center"><FONT size="2"><B>Report of Foreign Private Issuer</B>
</FONT>

<P align="center"><FONT size="2"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>
</FONT>

<P align="center"><FONT size="2">For the month of March&nbsp;2006
</FONT>
<P align="center"><FONT size="2">Commission File Number 000-31062
</FONT>

<CENTER>
<P align="center"><FONT size="6"><B>Oncolytics Biotech Inc.</B></FONT>
<HR size="1" width="45%" noshade>
<FONT size="2"><I>(Translation of registrant&#146;s name into
English)</I>
</FONT>

</CENTER>

<CENTER>
<P align="center"><FONT size="2"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="45%" noshade>
<I>(Address of principal executive offices)</I>
</FONT>
</CENTER>

<P align="left"><FONT size="2">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.
</FONT>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="70%">
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="center" valign="top"><FONT size="2">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;</FONT><FONT
face="wingdings">&#111;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
Form&nbsp;40-F&nbsp;&nbsp;&nbsp;</FONT><FONT
face="wingdings">&#254;</FONT></TD>
</TR>
</TABLE>
</CENTER>

<P align="left"><FONT size="2">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>
</FONT>

<P align="left"><FONT size="2"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.
</FONT>

<P align="left"><FONT size="2">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>
</FONT>

<P align="left"><FONT size="2"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.
</FONT>

<P align="left"><FONT size="2">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.
</FONT>
<CENTER>

<TABLE cellspacing="0" border="0" cellpadding="0" width="70%">
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">Yes&nbsp;&nbsp;&nbsp;</FONT><FONT
face="wingdings">&#111;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">No&nbsp;&nbsp;&nbsp;</FONT><FONT
face="wingdings">&#254;</FONT></TD>
</TR>
</TABLE>
</CENTER>

<P align="left"><FONT size="2">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</FONT>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P align="center"><FONT size="2">&nbsp;</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Signatures</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center"><FONT size="2"><B>SIGNATURES</B>
</FONT>

<P align="left"><FONT size="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
</FONT>

<P>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>

<TD colspan="3" align="left" valign="top"><FONT size="2"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</FONT></TD>
</TR>
<TR><TD><FONT size="2">&nbsp;</FONT></TD></TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR><TD><FONT size="2">&nbsp;</FONT></TD></TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">Date  March&nbsp;27, 2006</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
By:
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">/s/ Brad Thompson
<HR size="1" noshade width="60%">
Brad Thompson<BR>
President and CEO</FONT></TD>
</TR>
</TABLE>
</CENTER>

<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="o30790o3079000.gif" alt="(ONCOLYTICS BIOTECH INC LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Oncolytics Biotech Inc. Announces Issuance of 15th U.S. Patent</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY, AB &#151; March&nbsp;27, 2006 </B>&#151; Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)
(&#147;Oncolytics&#148;) has been granted U.S. Patent 7,014,847 entitled &#147;Methods for Preventing Reovirus
Recognition for the Treatment of Cellular Proliferative Disorders.&#148; The claims describe methods for
preventing reovirus recognition by the host immune system, while concurrently or subsequently
administering reovirus, resulting in substantial lysis of the proliferating cells.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;The claims in this U.S. patent allow manipulation of the immune system that may enhance the
effectiveness of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> treatment,&#148; said Dr.&nbsp;Matt Coffey, Chief Scientific Officer of
Oncolytics. &#147;The use of immune modulation with this class of biologic agent is a growing and
promising field of research and we are pleased to have secured patent protection for this new
treatment modality.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Oncolytics Biotech Inc.</B><BR>
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I and
Phase I/II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, its proprietary formulation of the human reovirus, alone
and in combination with radiation. For further information about Oncolytics please visit
<U>www.oncolyticsbiotech.com</U>
</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><I>This news release contains forward looking statements, within the meaning of Section&nbsp;21E of the
Securities Exchange Act of 1934, as amended. Forward looking statements, including among others,
the Company&#146;s belief as to the importance of the issuance of this patent, the safety and efficacy
of the reovirus, the Company&#146;s expectations as to the potential applications of the patented
technology and other statements relating to anticipated developments in the Company&#146;s business and
technologies, involve known and unknown risks and uncertainties that could cause the Company&#146;s
actual results to differ materially from those in the forward looking statements. Such risks and
uncertainties include, among others, the efficacy of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a cancer treatment, the success
and timely completion of clinical studies and trials, uncertainties related to the research and
development of pharmaceuticals and uncertainties related to the regulatory process. Investors
should consult the Company&#146;s quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward looking
statements. Investors are cautioned against placing undue reliance on forward looking statements.
The Company does not undertake to update these forward looking statements.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size:1pt">
    <TD width="38%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Oncolytics Biotech Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cathy Ward
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nick Hurst</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">210, 1167 Kensington Cr NW
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Toronto Street</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Calgary, Alberta T2N 1X7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toronto, Ontario M5C 2B8</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Tel: 403.670.7377
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 416.815.0700 ext.226</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fax: 403.283.0858
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 416.815.0080</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>cathy.ward@oncolytics.ca</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>nhurst@equicomgroup.com</U></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>www.oncolyticsbiotech.com</U></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">The Investor Relations Group
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">RenMark Financial Communications</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Damian McIntosh
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">John Boidman</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">11 Stone St, 3rd Floor
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2080 Rene Levesque Blvd. W.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">New York, NY 10004
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montreal, PQ H3H 1R6</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Tel: 212.825.3210
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 514.939.3989</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fax: 212.825.3229
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 514.939.3717</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>dmcintosh@investorrelationsgroup.com</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>jboidman@renmarkfinancial.com</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">-30-
</DIV>



<P align="center" style="font-size: 10pt">
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o30790o3079000.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o30790o3079000.gif
M1TE&.#EA>P)4`-4@`$!`0,#`P("`@/#P\-_>U;Z]JIV;?^#@X-#0T+"PL)"0
MD%!04/?W]6!@8#`P,*"@H(2"7^?FWZVLE'!P<)63=._OZA`0$,[-O\;%M8R+
M:2`@(-;6RJ6DBK:TGWQZ5````/___P``````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````"'Y!`$``"``+`````![`E0```;_
M0)!P2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZO^"P>$P>5@B;@KI`(##*\+A\
M3J_;[_B\?L]G;CH&'H*#A!X0!@41?8N,C8Z/D)&2DY(1$A"%F9H9!164GZ"A
MHJ.DI:98!(&:JZL2GJ>PL;*SM+6V4!&JF102!1=M;1@%!AFM;[?(R<K+S,UB
M'9H2%\=*%1@4F1`7SMS=WM_@LQ'8A!D8U$\5$ID2Z.'O\/'R\U\;F(,0&%?J
MA12O]``#RGH@X`"1`P:'!%BX)$"1`0B,('@`XL#"A0.(7(QX,6,4!1[%3`SP
M($'")`@"G$P9P*/%``A>.@2Q\"2E"X4XN*M"@)P@_PB*!`H="FJ!@`86$@:P
M,!-$`@4@%"1`<F`"`"((``C`NF#F`@!@+80$,4##`B$)'-A\LF"MDK%.!BR`
M2M9!TR0+Q`Y9$'&O!B$-/GA,<!843GS;N#!8AR\HT<>0^Y@$O%4(@*9_A60^
M$N`J$0&502!PX!&BD`&>B6@5#0#NEP%TH30H+`3!U"4"')`6$KKV!X,'/LQ\
MX!;2X9^.NQPWM#.R\^=E0@J(?5G(`0=#U"+I7`3T$``/8!9Y$/N[@*QC%S9`
M`)L\@-L*`FP=<+Z]@O?6GX:7NUYT@J=D*>#>;:=]0-%!!YP'0'$%6=``;T9H
M4)F#@($2P3T>4)"<%\M1T/\<=""&Z,4"(55'4VHF&L'=9Y4%ET``"SRXEUL`
MY&63``X]<)4`)")@@6A;432:0SQ"]",(V`V0%`C>R<7;!$SV>*00`0BGX@<3
MN<8D31]`U9L0"OR50&`#'%!>)`P4\],_82PG@8APQKD%2:K-M"((*19Q)V^5
MW;FD$-@9`4`#NH6DP4();.4="!]49$$"'E6W:*.,9B1ID"W^.*E&5AI!*1*5
M*?!!HD:X^*`%#TR@I2.,&;)AFX1L(.>LM$(Q41$F'H!B<2=V5UE6W\T$H*`"
M#%"H$+^QB"Q:%I"()Y&543H!2(5YMRBC3$9;1)='?'I$:$C1IMH"4$[@`)24
M$!#_JQRM0O!AK?#2"IMUD6(V1&9N[9GMO=\EU$!QJQD;J`-])J@M>\9"=>FR
M3B70U[X)I(;=ID0TL)EUV";1FP/>#O$`EA49^(F:'G0P1YJ#O!GORO`:"]:@
MV1$(H%1,)DM$6D5,@"Z34`VP<Z`/:2!C`A^02+3.4.E,EF`!).V0`U,I/8!@
M2!IU7E0+3.5`1#1+3?40J+554;%3>P1U$7R!?>39IVVVVR3'9?!N&.H.PB;+
M>(<HDTI4UJ000V05=-!%0[#T,.'Y<;801X0C@"-9-2T^P(L.L?322^R%I\!1
M`1HT.=\#1"Y>$8X_3A/@D&*%4>%HC742KXV0G!@=K:J<__?MN(/],"D-$'A7
MK<<9<$<%A,R=^_'(0Q*``X."Q+(NL]?1JC[)5V_]]7T0+T@&>40P"/?8AR_^
M^&-@,(C)>?AT-_GLM^^^$QP,\BH=Y@M"_?OXYZ\_"-_OX;T@'-B?`$D!F@",
M25RGF0`"1Z01N_CL2P,4PO\\8+L\W`-\2(@`,-9'!&`8KP@,((`PU(`!`LPO
M"6<880%*R$$DG*$-3P`&`5K806`408,RS*$.9XB$#>*"`&OPA1N:4($T!'&%
M0V0?P<`F(SVEY@L?N\O"XK([[&U@$`7@@RZ40`B@]!"+1.P`R;+!@1,*01UC
M+`0$)$``)NBBC4WPB0>B!T*?>/^("*Q@10"-4#</",\/',!0)C*`/B,PH`!I
M'&0':)B[CXWG-"VA4FHL,C@B0&152&C`;.J4+4H6KBD9<4@#9A(Z3.:M`(.`
MHQZ@(0A5&D&-LN(C&)6PF"X:H`,%D(`NVH&$6N+CE@4`Q!@-P,@W/J%5<SP"
M`^SH#@X8X)G0+`<TH1G+(O3QCTD@P!@IP`$U$.,GU21"!(:Y!D!@R(OA^\H1
M$`"EKO2*22DY%`@>\`!CA<X!]]D<R![01(DH``$V>Q:3`*#`)!7K/O-\E`;2
MHH`#L!,$[JP>*@5AQCE,U`.N+((FZ`B"/F8Q"1<:A`$R*D&2#F&9(C5I*AJ3
M!&,>DQ#_=$2I(.[HQD%\4`C75`(K#=$)0_+P""3CI1$J<(%$C`\L1_C/OE:T
M-B(9I#KXT8Q#&IJ$!F3$`4V<XD(WMQ"0?:TZ2KT6\K;(A^.85`CX@*DU9WF$
MD`J"H_`;Q!Z3$+^??,BE+QW$[&2:H9N"@*Q-R"D2=HI.*&B/HA$DU'8(LY45
M:2`B"T++`^PB4"'H"`0[,X)<%C(!O0AT41,00)XR5ED#&L5Z@-5#'^_W2D$8
M8#G1\VA+4T:%"7J`D2!@`"%82P2\YE40LN(K39N0VB4(5I:II()/,C`-`7[,
M+0#RSHH",,K;3`"R#LD3J@[TK9-H@"Y3%,`#R,6Z3X'52Q#$_UUQ\2!;)(@4
M!/5[ZQ#::P3;5E0)%Z4`<=][!-_^%@(]&<1P]RN(&/+7"*W2+Q48H`O7]F(#
M][6>`\1%$?R$]IW]&0+5*)LG`>#K7V@CP@0R,T6K/L`"$2$.:2^#FJBE]W;K
MO<,56YD$_B(S,?0M0GP]4(5681._^$""?W]+B`$3F,=..&X1=%%(*JQ4$Q#@
M``9P>SSZ:(4@&5&`!:8#-06DK0$`L,`''K0`?,Z&,,X[C8QTU1LO)\3*_YS+
MY*K;E\XNU"E158!=M,SEW^%NIU2&PT7/RC_7#N'&'65K$2Z*Y"G4U8]-8+20
MDTL%9/95"C'^HJ'[J^@J1&`8B02@7__;IU2T-,%AA8-=!*$P:#ZTVKTS)4*[
M%-'I(<Q8$*->=)"9L-,?]Y;25-"%W*:0Z2,H^=<`]`(!+G")(J^Z8ETA216-
M((`)]%/5SW;"<7A[!UV\BQ!%F'6MA<``#'';";8E]!!\4D%D8]0*%_THI@=A
MX$T;X3CN`H,O$9MMIXC7E%1*<[^ST,=VW^$>$.`BO<.=5D'(VPCQ!7"P#ZQI
M&G/:XE2(]\0+G&2*%X&98$CWP$=^!P'OX;"^UNC"&5Z(AR.8$*[(X(?XJA,D
MV.-\L\7X%#1.[)4SX=CB)!ES08J$"US`C!6P(\F73@?UZ2&^+E<YQXVP4X<O
M`0."I(`:1)C_RV)HJ)>/]D`W-]"&"W1`CN<>@BXH,,VVIYT(/)_WU'_N<1"&
M/<HK-*(J#+YC`_2BA-XL<H293G@M7/3M<?!)1<%==$)$W9"(S*,?U?UD5JP1
MMPUFQ>-U;?6>S]VX=>=CLUF1`0[<38R2WQ[BDS>`\/R'0%-HO1+VMC@JF6YU
M??,S0FI#N-`QA"6`P]T$%3R\_BEAA(@'HAH&?T:]`_/HZ4@#()[9338XP8A'
MS/X'/[U\*AAQ]3I60SB-*PQ=(H(-C`RA&IP)S6Y>(-#'BUA"+EN%*BFA@(0B
MR5FJW=FIE"4UJ`$72T%*@=$7_#0`+@,60(,[)*-N9+!3359X$B@&_\&Q.R_V
M!!U3!+<A6JUS(/2'%$V47BEB+&<Q`#+"'FAQ@?$27RD7!^5F-Q,8@V(P8D4P
M?_*!@`)R'[<1'L6"%DU#*0;T3]_R1!X!([Q!-`<B@G<!4&/B&AF6.R^H<W)P
M42TH@U:(!4AE!)O#,U%B)%&A*%[B?XT"+$9(;4\T!*:C*""CA-TQ*D>P@+F3
M7W5P6.]VA7:H!5GX$!!Q6IN"@`AP6IM!*0C!@6:H63M3&3;"AD00)F=($YD%
MA>9&![I0A7=8B5`@`%-B21-@,/N"+3[#B9]"*3BB+[QQAO3Q&:>A&X]H&7<A
M'P=@`6=R7=:S8\QG>(0`?Y:8BZ4B,D-@$/^CM"^;\HO>(4_80A#OU!UGF&81
M$1JOV(B5)1HR(BJ[XXRY(VRY9@5]Y`&;9X9@$5J"LP1LU@2P\17="'N@\C+H
MJ((G@H[@T03R\3)SL03R1P0+L$!7,(^XL1I[T4]*D`!6`18-P%T#]``:X(%3
M$2.$L1Y>PQ\)Z3A0\S%/81?FXF<6$Q*$\C((V!H*X8QL<QTG80':`8W84P$8
M8F1?X%:0Y@0`T"6<)6;3IB<?0(TW8P&PB"@+$).FQ!(W.8K8)@!%<Q%\\Q8K
MV3L+(83WURG(DH%7X)-^)B@?\`%O\Y1,,!H?,`$7057/UGKBE1`)PAX-)3HQ
M41_.XXH4`1M3@97_GP0XOE=[B%,;*N(WB`-\5/*2QW-KEQ8&*)EO*CEFH'&3
M_,@9,<D$&N"&1,`Q9P(J2(D;,0D:`F".1Q`8?ZF85@,:4LD%3,D$*_DQ*,8H
M2HDK5:F+H$D&.V:26I"7M8@G?%EM%E"0#1&82R!FYKB2ZL@;B7F4!`,:CNF4
MARF9C.F3G5D%E[D$*[D0-/DQOWDOA!F:ROD%R)0!I^D$.^8!XX>9G6*"KID$
M52*3:`B5)U$E(,,$P0F>G_D$1(,J8-.3B5F96Q">23"<%<$QZID$'\,V9`%P
MH$&7RYF?0F!IVR@%#!!VR10%-_F43RDTV`90]J@B-ZD!8>8@^%D$HM*4_T<@
M*@1:H$QP`!;S`8/9+(IY%S39!>R)!#?9%S[S`9F(G1DZF!JPBD4P&P^JG\L9
MG13@@$V`=5WTG#":HSH:!S='"",U!0QP`6GD#SM:I$9Z<IGG`>8`?QLP>H00
M@4<:I5(:!Q<@2-_3"VUP#&>0!@9@I3-%HU,:IF*:!8?DI:DW2'`UIFJZIF1Z
M`7)TIG(UG6PZIW1J!=:0I%#&`<U5IWS:IU@0`=CG=VOP4WY:J(9ZJ(B:J(JZ
MJ(S:J([ZJ)`:J9(ZJ91:J99ZJ9B:J9JZJ9S:J9[ZJ:`:JJ(ZJJ1:JJ9ZJJB:
MJJJZJJS:JJ[ZJK`:J[(ZJ[1:J[9ZJ[B:J[IZAX19P8Z^^JO`&JS".JS$6JS&
M>JS(FJS*NJS,VJS.^JS0&JW2.JW46JW6>JW8FJW:NJW$:I45^JW@&J[B.J[D
M6J[F>J[HFJ[JNJ[LVJ[N^J[P&J_R.J_T6J_V>J_XFJ_ZNJ_\VJ_C>AG^&K`"
<.[`$6[`&>[`(F[`*N[`,V[`"JYV[&K%Q$@0`.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
